Lisata Therapeutics (LSTA): CEO received 81K shares

81K

Shares

Traded

Jan 9, 2026

Filed

Jan 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

What came next

1. Jan 20, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
2. Feb 27, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
3. Mar 6, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
4. May 3, 2026Company filing · Form 8-K · Material agreementSigned an important agreement

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lisata Therapeutics

OQRO holds no insider, Congress, fund or contract record for Lisata Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LSTA page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans